Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy
Status:
Recruiting
Trial end date:
2023-06-25
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well abatacept, ixazomib citrate, and dexamethasone work in
treating patients with multiple myeloma that is resistant to chemotherapy. Abatacept may
block certain proteins that are present on multiple myeloma cells that have been shown to
protect against chemotherapy. Drugs used in chemotherapy, such as ixazomib citrate and
dexamethasone, work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
abatacept, ixazomib citrate, and dexamethasone may work better at treating patients with
multiple myeloma resistant to chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborators:
Bristol-Myers Squibb National Cancer Institute (NCI)